Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease

Danielle E Anderson, Velraj Sivalingam, Adrian Eng Zheng Kang, Abhishek Ananthanarayanan, Harsha Arumugam, Timothy M Jenkins, Yacine Hadjiat, Maren Eggers, Danielle E Anderson, Velraj Sivalingam, Adrian Eng Zheng Kang, Abhishek Ananthanarayanan, Harsha Arumugam, Timothy M Jenkins, Yacine Hadjiat, Maren Eggers

Abstract

Introduction: As of 22 June 2020, Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV)-2 has infected more than 8.95 million people worldwide, causing > 468,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in vitro virucidal activity of topical and oral povidone-iodine (PVP-I) products against SARS-CoV-2.

Methods: Suspension assays were used to assess the virucidal activity of PVP-I against SARS-CoV-2. Products were tested at a contact time of 30 s for virucidal activity. Viral titres were calculated using the Spearman-Kärber method and reported as median tissue culture infectious dose (TCID50)/mL.

Results: All four products [antiseptic solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved ≥ 99.99% virucidal activity against SARS-CoV-2, corresponding to ≥ 4 log10 reduction of virus titre, within 30 s of contact.

Conclusion: This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination, and could be readily integrated into coronavirus disease, COVID-19, infection control measures in hospital and community settings.

Keywords: Anti-infective agents; COVID-19; PVP-I; Povidone-iodine; SARS-CoV-2; Upper respiratory tract infections; Viruses.

References

    1. World Health Organisation. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020: World Health Organisation. 2020. . Accessed 11 May 2020.
    1. Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020;92:214–217. doi: 10.1016/j.ijid.2020.01.050.
    1. Johns Hopkins University and Medicine. Coronavirus Resource Center: John Hopkins University. 2020. . Accessed 22 June 2020.
    1. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163–188. doi: 10.1016/bs.aivir.2018.01.001.
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017.
    1. World Health Organisation. Interim recommendations on obligatory hand hygiene against transmission of COVID-19: World Health Organization. 2020. . Accessed 18 Apr 2020.
    1. Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe. 2020;1:e10. doi: 10.1016/S2666-5247(20)30003-3.
    1. Vogt PM, Hauser J, Mueller S, Bosse B, Hopp M. Efficacy of conventional and liposomal povidone-iodine in infected mesh skin grafts: an exploratory study. Infect Dis Ther. 2017;6(4):545–555. doi: 10.1007/s40121-017-0172-z.
    1. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther. 2018;7(2):249–259. doi: 10.1007/s40121-018-0200-7.
    1. World Health Organisation. WHO R&D Blueprint COVID 19 Experimental Treatments: World Health Organisation. 2020. . Accessed 18 May 2020.
    1. Kawana R, Kitamura T, Nakagomi O, et al. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatology. 1997;195(Suppl 2):29–35. doi: 10.1159/000246027.
    1. Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology. 2006;212(Suppl 1):119–123. doi: 10.1159/000089211.
    1. Eggers M, Eickmann M, Zorn J. Rapid and effective virucidal activity of povidone-iodine products against middle east respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus Ankara (MVA) Infect Dis Ther. 2015;4(4):491–501. doi: 10.1007/s40121-015-0091-9.
    1. Spearman C. The method of ‘right and wrong cases’ (‘constant stimuli’) without Gauss's formulae. Br J Psychol. 1908;2:227–242.
    1. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv Exper Pathol Pharmakol. 1931;162:480–483. doi: 10.1007/BF01863914.
    1. Comité Européen de Normalisation. EN14476:2013 + A1:2015: Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of virucidal activity in the medical area. Test method and requirements (Phase 2/Step 1) 2015.
    1. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19) Treasure Island, FL: StatPearls; 2020.
    1. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406–1407. doi: 10.1001/jama.2020.2565.
    1. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26(7):1470–1477. doi: 10.3201/eid2607.200282.
    1. Eggers M, Koburger-Janssen T, Ward LS, Newby C, Müller S. Bactericidal and virucidal activity of povidone-iodine and chlorhexidine gluconate cleansers in an in vivo hand hygiene clinical simulation study. Infect Dis Ther. 2018;7(2):235–247. doi: 10.1007/s40121-018-0202-5.
    1. Australian Dental Association. Managing COVID-19 Guidelines. 2020. . Accessed 21 June 2020.
    1. Centers for Disease Control and Prevention. Guidance for dental settings: interim infection prevention and control guidance for dental settings during the COVID-19 response: centers for disease control and prevention. 2020. . Accessed 21 June 2020.
    1. Nagatake T, Ahmed K, Oishi K. Prevention of respiratory lnfections by povidone-lodine gargle. Dermatology. 2002;204(Suppl 1):32–36. doi: 10.1159/000057722.
    1. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–469. doi: 10.1038/s41586-020-2196-x.
    1. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–574. doi: 10.1016/S1473-3099(20)30196-1.
    1. Gui D, Pepe G, Magalini S. Just one more hygiene practice in COVID-19. Eur Rev Med Pharmacol Sci. 2020;24(7):3438–3439.
    1. O’Donnell VB, Thomas D, Stanton R, et al. Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function. 2020;1:zqaa002. doi: 10.1093/function/zqaa002.
    1. Mady LJ, Kubik MW, Baddour K, Snyderman CH, Rowan NR. Consideration of povidone-iodine as a public health intervention for COVID-19: Utilization as "Personal Protective Equipment" for frontline providers exposed in high-risk head and neck and skull base oncology care. Oral Oncol. 2020;105:104724. doi: 10.1016/j.oraloncology.2020.104724.
    1. Kirk-Bayley J, Challacombe S, Sunkaraneni S, Combes J. The use of povidone iodine nasal spray and mouthwash during the current COVID-19 pandemic may reduce cross infection and protect healthcare workers. 2020. 10.2139/ssrn.3563092.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren